Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)
Recruiting now
Conditions studied: NSCLC
In brief
Non-small cell lung cancer (NSCLC) is one of the leading causes of death in Western countries. Today, a new frontier in the fight against cancer is immunotherapy, a treatment that aims to "awaken" the patient's immune system to help it recognize and attack cancer cells. Among the various approaches, there is significant focus on therapies that activate T lymphocytes, a type of immune cell, encouraging them to react against the tumor. These treatments have led to important progress and represent a hope for the future.
Key facts
- Study ID
- NCT06823401
- Run by
- Fondazione Ricerca Traslazionale
- People needed
- 270
- Starts
- 2021-05-20
- Expected to finish
- 2029-12-31
- Last updated by the study team
- 2026-02-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed diagnosis of NSCLC
- Possibility to obtain blood samples
- Patient candidate, in any therapy line, for a therapy with any checkpoint inhibitor including single agent pembrolizumab, single agent atezolizumab, single agent nivolumab, single agent durvalumab or combination of nivolumab and ipilimumab
- Performance status 0-2 (ECOG)
- Patient compliance to trial procedures
- Age ≥ 18 years
- Written informed consent
You may not qualify if…
- No possibility to obtain blood samples
- Previous therapy with any checkpoint inhibitor
- Patient candidate for a therapy with a checkpoint inhibitor in combination with chemotherapy or any other non-checkpoint inhibitors
- Pregnancy or lactating
Where it is running
- Istituto Tumori Regina Elena — Roma, RM, Italy (enrolling)
- Istituto Tumori Regina Elena — Roma, RM, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.